4/A//SEC Filing
Regnante Keith 4/A
Accession 0001415889-25-002024
CIK 0001664710other
Filed
Jan 23, 7:00 PM ET
Accepted
Jan 24, 4:15 PM ET
Size
6.5 KB
Accession
0001415889-25-002024
Insider Transaction Report
Form 4/AAmended
Regnante Keith
CHIEF FINANCIAL OFFICER
Transactions
- Exercise/Conversion
Common Stock
2024-01-04$16.00/sh+40,000$640,000→ 40,000 total - Sale
Common Stock
2024-01-04$45.29/sh−40,000$1,811,600→ 0 total
Footnotes (2)
- [F1]This amendment is being filed to correct the Date of Earliest Transaction and the Transaction Date of each transaction listed in Table I.
- [F2]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023.
Documents
Issuer
Keros Therapeutics, Inc.
CIK 0001664710
Entity typeother
Related Parties
1- filerCIK 0001682068
Filing Metadata
- Form type
- 4/A
- Filed
- Jan 23, 7:00 PM ET
- Accepted
- Jan 24, 4:15 PM ET
- Size
- 6.5 KB